(Q35967376)

11 August 2017

1 reference

title

Emerging therapies for herpes viral infections (types 1 - 8). (English)

1 reference

11 August 2017

Arun Chakrabarty

1

1 reference

11 August 2017

Katie R Pang

2

1 reference

11 August 2017

Jashin J Wu

3

1 reference

11 August 2017

Julio Narvaez

4

1 reference

11 August 2017

Michael Rauser

5

1 reference

11 August 2017

David B Huang

6

1 reference

11 August 2017

Karl R Beutner

7

1 reference

11 August 2017

Stephen K Tyring

8

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Expert Opinion on Emerging Drugs

11 August 2017

published in

1 reference

11 August 2017

volume

9

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

237-256

1 reference

A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Studies on shingles: is the virus ordinary chickenpox virus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

The etiologic agents of varicella and herpes zoster; isolation, propagation, and cultural characteristics in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Infectious mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Primary Infection with Epstein-Barr Virus in Infants in the United States: Clinical and Serologic Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Intrafamilial transmission of Epstein-Barr virus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Advances in the management of AIDS-related cytomegalovirus retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Cytomegalovirus infection in immunocompetent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Treatment of recurrent herpes simplex labialis with oral acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Human herpesvirus 6: molecular biology and clinical features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Human herpesvirus 8, Kaposi's sarcoma, and associated conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Serologic evidence of human herpesvirus 8 transmission by homosexual but not heterosexual sex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Biochemical basis for increased susceptibility to Cidofovir of herpes simplex viruses with altered or deficient thymidine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Foscarnet-resistant herpes simplex virus infection in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Relation between herpes simplex viruses and human immunodeficiency virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Selective decline in cellular immune response to varicella-zoster in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Pathogenesis of post-herpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Prolonged Herpes-Zoster Infection Associated with Immunosuppressive Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Infection with varicella-zoster virus after marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Varicella-zoster virus: infection, control, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Ambulatory management of varicella-zoster virus infection in immunocompromised cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Comparable aciclovir exposures produced by oral valaciclovir and intravenous aciclovir in immunocompromised cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Acyclovir and Epstein--Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Effect of acyclovir on infectious mononucleosis: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Blood stem-cell transplantation for chronic active Epstein-Barr virus with lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Antiviral drugs in current clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Imiquimod 5% cream (Aldara).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Penciclovir cream for the treatment of herpes simplex labialis. A randomized, multicenter, double-blind, placebo-controlled trial. Topical Penciclovir Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Virally targeted therapies for EBV-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Immunotherapy of cytomegalovirus infection after stem-cell transplantation: a new option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Potent, selective and cell-mediated inhibition of human herpesvirus 6 at an early stage of viral replication by the non-nucleoside compound CMV423.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Selective activity of various antiviral compounds against HHV-7 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Advances in antiviral therapy in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. Results of an international, multicenter, double-blind, randomized clinical trial. The Valaciclovir International Herpes Simplex Virus Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Once-daily valacyclovir to reduce the risk of transmission of genital herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Famciclovir for the Treatment of Acute Herpes Zoster: Effects on Acute Disease and Postherpetic Neuralgia: A Randomized, Double-Blind, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Effect of food on the relative bioavailability of oral ganciclovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Human pharmacokinetics of the antiviral drug DHPG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Clinical uses of cidofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Foscarnet nephrotoxicity: mechanism, incidence and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Minimising the dosage-limiting toxicities of foscarnet induction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Foscarnet-Induced Hypocalcemia and Effects of Foscarnet on Calcium Metabolism*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Oral bioavailability and in vivo efficacy of the helicase-primase inhibitor BILS 45 BS against acyclovir-resistant herpes simplex virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Primary human herpesvirus 8 infection generates a broadly specific CD8(+) T-cell response to viral lytic cycle proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.2.237

21 January 2018

Identifiers

DOI

10.1517/14728214.9.2.237

1 reference

11 August 2017

1 reference